Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy

Por Sokolosky, Melissa L., Stadelman, Kristin M., Chappell, William H., Abrams, Stephen L., Martelli, Alberto M., Stivala, Franca, Libra, Massimo, Nicoletti, Ferdinando, Drobot, Lyudmyla B., Franklin, Richard A., Steelman, Linda S., McCubrey, James A.
Publicado em 2011

A Phase I Study of the First-in-Class Anti-Mitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies

Por Pardee, Timothy S., Lee, King, Luddy, John, Maturo, Claudia, Rodriguez, Robert, Isom, Scott, Miller, Lance D., Stadelman, Kristin M., Levitan, Denise, Hurd, David, Ellis, Leslie R., Harrelson, Robin, Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L
Publicado em 2014

Suppression of PTEN Function Increases Breast Cancer Chemotherapeutic Drug Resistance while Conferring Sensitivity to mTOR Inhibitors

Por Steelman, Linda S., Navolanic, Patrick M., Sokolosky, Melissa L., Taylor, Jackson R., Lehmann, Brian D., Chappell, William H., Abrams, Steven L., Wong, Ellis W.T., Stadelman, Kristin M., Terrian, David M., Leslie, Nick R., Martelli, C. Alberto M., Stivala, Franca, Libra, Massimo, Franklin, Richard A., McCubrey, James A.
Publicado em 2008

ALTERATION OF AKT ACTIVITY INCREASES CHEMOTHERAPEUTIC DRUG AND HORMONAL RESISTANCE IN BREAST CANCER YET CONFERS AN ACHILLES HEEL BY SENSITIZATION TO TARGETED THERAPY

Por McCubrey, James A., Sokolosky, Melissa L., Lehmann, Brian D., Taylor, Jackson R., Navolanic, Patrick M., Chappell, William H., Abrams, Stephen L., Stadelman, Kristin M., Wong, Ellis WT, Misaghian, Negin, Horn, Stefan, Bäsecke, Jörg, Libra, Massimo, Stivala, Franca, Ligresti, Giovanni, Tafuri, Agostino, Milella, Michele, Zarzycki, Marek, Dzugaj, Andrzej, Chiarini, Francesca, Evangelisti, Camilla, Martelli, Alberto M., Terrian, David M., Franklin, Richard A., Steelman, Linda S.
Publicado em 2008